GeneDx Holdings Corp. Securities Fraud Lawsuit Lead Plaintiff Deadline Approaching
Investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as lead plaintiff in a securities fraud lawsuit.
Law firm Rosen Law Firm is notifying purchasers of GeneDx Holdings Corp. common stock (NASDAQ: WGS) of an upcoming deadline to serve as lead plaintiff in a class action lawsuit. The deadline for investors who bought GeneDx stock between April 16, 2025, and May 4, 2026, inclusive, is August 3, 2026.
The lawsuit alleges that GeneDx Holdings Corp. made false or misleading statements and omissions regarding the impact of its acquisition of Fabric. The complaint claims that GeneDx repeatedly told investors that the Fabric acquisition would improve its financial performance and create efficiencies. However, the lawsuit alleges that the company knew of or recklessly disregarded significant problems with Fabric's viability that would negatively impact GeneDx's overall business and operations.
According to the suit, when the true details of these problems entered the market, investors suffered damages. Investors who purchased GeneDx common stock during the Class Period may be entitled to compensation without out-of-pocket fees or costs under a contingency fee arrangement.
Rosen Law Firm urges investors to contact them for information on the class action. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. The firm also notes that no class has yet been certified, and investors are not represented by counsel unless they retain their own. Their ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.